Loading...
NPI 1265418669 · Dallas, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Corporation Of America is a clinical medical laboratory provider located in Dallas, Texas. This profile covers 513 Medicare and 392 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Corporation Of America |
| Address | 7777 Forest Ln Bldg C350 |
| City | Dallas |
| State | TX |
| ZIP | 75230 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 16, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $77.4M |
| Medicare | $34M |
This provider has materially larger Medicaid activity than Medicare activity, reporting Total Medicare revenue: $34M versus Total Medicaid revenue: $77.4M, so it operates with a meaningful Medicaid-heavy payer mix rather than being effectively single-payer. The scale difference suggests Medicaid contract coverage and state-level lab routing are central to its revenue base.
Revenue concentration differs by payer: the top 3 Medicare codes account for 34.5% of this provider's total Medicare revenue, driven by 80053 ($3M revenue, 304.5K claims, 12.9% of Medicare revenue), 84443 ($2.6M revenue, 165.2K claims, 11.2% of Medicare revenue), and 80061 ($2.5M revenue, 190.1K claims, 10.5% of Medicare revenue). On Medicaid the top 3 codes account for 26.5% of total Medicaid revenue, with 80050 ($5.9M revenue, 268.2K claims, 10.6% of Medicaid revenue), 87491 ($4.6M revenue, 207.9K claims, 8.2%), and 87591 ($4.3M revenue, 203K claims, 7.7%) anchoring state-level revenue.
The code mix indicates a high-throughput clinical reference lab operation: large volumes of routine chemistry and hematology panels (80053, 80061, 85025), endocrine and metabolic monitoring (84443, 83036), and mass specimen collection (36415 with 278.5K claims). At the same time it processes high-volume STD NAATs (87491, 87591 with >200K Medicaid claims each) and large-scale infectious disease testing including U0003 (79.4K Medicaid claims, $4.2M revenue), illustrating both routine outpatient testing and public-health or population-screening workflows.
Nationally in Medicare this provider is a dominant volume outlier on many common laboratory codes: examples include 80053 (ranks #19 of 26416 providers nationally, 100th percentile; extreme outlier), 84443 (ranks #19 of 19722, 100th percentile; extreme outlier), and 80061 (ranks #20 of 21671, 100th percentile; extreme outlier). Those percentile and rank positions indicate the provider sits at the top of national volume distributions for routine and endocrine assays rather than being a modest regional contributor.
State-level competitive standing in Texas is similarly leading: 80050 ranks #3 of 148 providers in-state (99th percentile; extreme outlier) and 87150 ranks #1 of 52 providers in-state (100th percentile; extreme outlier), while many other Medicaid codes rank in the 97–100th percentiles. These in-state ranks show the provider is a major laboratory player in Texas across both routine panels and specialized testing services.
Operational scale is evident from very high claim counts for specimen-collection and automated testing codes: 36415 has 278.5K Medicare claims and CBC/other counts appear among the highest (85025 with 269K Medicare claims and 594K Medicaid claims). The combination of large claim volumes and predominance of panel/automated codes implies centralized processing capacity and significant logistics for sample intake and automated analysis.
The provider also offers higher-complexity and higher-reimbursement assays alongside routine testing, evidenced by Medicaid-level genomic and specialized codes such as 81420 ($3.1M Medicaid revenue, 13.7K claims) and 81220 ($1.3M Medicaid revenue, 4.8K claims), plus Medicare code 81490 ($295.8K revenue, 359 claims). This breadth—routine high-volume assays plus genomic and algorithmic tests—indicates a mixed-service laboratory model that supports both standard clinical testing and specialized diagnostics.
The provider’s NPI was enumerated on 2005-12-16 (~21 years ago), reflecting longstanding enrollment in federal programs; combined with persistent top-percentile ranks across many codes, this tenure supports interpretation as an established, large-scale reference lab with durable payer relationships and operational continuity.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
513 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 304,540 | $10 | $3M |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 165,230 | $20 | $2.6M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 190,070 | $10 | $2.5M |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 278,450 | $10 | $2.2M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 268,950 | $10 | $2.2M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 70,650 | $30 | $2M |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 120,380 | $10 | $1.1M |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 24,590 | $40 | $983.8K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 84,010 | $10 | $672.1K |
| 84439 | The lab analyst performs a test to measure free thyroxine, or free T4, typically in patient serum. | 61,080 | $10 | $549.7K |
Showing 1–10 of 513
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 513 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
513 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 30 | 30 | 1,260 | $30 | $430.3K |
| 87798 | 209 | 300 | 790 | $30 | $265.1K |
| 81490 | 1 | 10 | 170 | $830 | $150.2K |
| 87900 | 5 | 10 | 50 | $130 | $111.5K |
| 81279 | 20 | 20 | 270 | $180 | $86.8K |
| 87801 | 116 | 120 | 170 | $70 | $86.5K |
| G0483 | 104 | 170 | 150 | $240 | $84.9K |
| 86003 | 6 | 10 | 8,740 | $10 | $78.5K |
| 87536 | 2 | 10 | 560 | $80 | $75.8K |
| U0003 | 15 | 60 | 100 | $70 | $64.7K |
Showing 1–10 of 513
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
392 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 268,220 | $20 | $5.9M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 207,950 | $20 | $4.6M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 203,000 | $20 | $4.3M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 79,370 | $50 | $4.2M |
| 80081 | The lab analyst performs an obstetric panel; this panel must include tests for a complete blood count with differential, a hepatitis B surface antigen test, a single–result test for HIV–1 antigens… | 69,930 | $50 | $3.4M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 13,650 | $230 | $3.1M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 616,440 | $10 | $3.1M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 271,980 | $10 | $3M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 195,980 | $10 | $2.7M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 561,290 | $1 | $2.2M |
Showing 1–10 of 392
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
392 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 4 | 20 | 950 | $300 | $3.2M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 4 | 20 | 180 | $200 | $923K |
| 80081 | The lab analyst performs an obstetric panel; this panel must include tests for a complete blood count with differential, a hepatitis B surface antigen test, a single–result test for HIV–1 antigens… | 4 | 20 | 250 | $40 | $821.3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 8 | 340 | 400 | $50 | $553.5K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 54 | 160 | 200 | $110 | $323.8K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 3 | 150 | 170 | $30 | $302.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 31 | 240 | 420 | $30 | $296.8K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 4 | 70 | 800 | $20 | $268.3K |
| 87536 | A lab tests a patient’s specimen to measure the amount of HIV–1 present. This may be referred to as viral load. | 4 | 20 | 1,370 | $40 | $268.3K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 4 | 30 | 200 | $20 | $262.8K |
Showing 1–10 of 392
Other providers in the same ZIP code as Laboratory Corporation Of America, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Columbia Hospital At Medical City Dallas Subsidiary LP | TX | General Acute Care Hospital | $0 | $21.5M |
| Anand Shivnani | TX | Radiation Oncology Physician | $1M | $0 |
| Vikas Bhushan | TX | Hematology & Oncology Physician | $943.9K | $0 |
| Tony Das | TX | Interventional Cardiology Physician | $845.2K | $0 |
| John O'connor | TX | Radiation Oncology Physician | $671K | $0 |
| Michael Isaac | TX | Cardiovascular Disease Physician | $641.7K | $0 |
| Jerald Sklar | TX | Dermatology Physician | $450.6K | $0 |
| Med City Dallas Outpatient Surgery Center, L.P. | TX | Ambulatory Surgical Clinic/Center | $407.6K | $0 |
| Mitchell Moskowitz | TX | Urology Physician | $326.1K | $0 |
| Zev Shulkin | TX | Ophthalmology Physician | $298K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.